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Abstract 
 
 The Liu lab focuses on synthesizing an ultra-low molecular weight heparin using a 
chemoenzymatic process that involves various enzymes and substrates. Current methods 
developed in the lab are used to synthesize and purify these biosynthetic enzymes and cofactors 
from E. coli crude lysates made with recombinant DNA technology. One of the key enzymes 
required for synthesis is pmHS2, with corresponding key substrates of UDP-GlcUA and UDP-
GlcNTFA. The purpose of this project was to optimize and purify essential reagents involved in 
the large-scale synthesis of heparin to improve the efficiency of production. Variables such as 
pH, temperature, and concentration were manipulated to determine optimal conditions for the 
reactions performed. Mass spectrometry and HPLC were used to analyze samples from the 
reactions and to determine the amount of product yielded. Nickle column chromatography was 
used to purify pmHS2 efficiently. With this project, variables were successfully optimized and 
optimal product yields were obtained. By producing a synthetic form of heparin that is 
reproducible and affordable for patients, many risks pertaining to the current production of 
heparin can be eliminated.  
 
Introduction 
 
 Heparan sulfate is a ubiquitous molecule that contains a variety of biologic functions that 
include regulation of blood coagulation, cell differentiation, and inflammatory responses.1 As a 
polysaccharide, it naturally contains repeating disaccharide units of N-acetyl-D-glucosamine 
(GlcNAc) and glucuronic or iduronic acid (GlcUA/IdoUA) that are highly sulfated with N- and 
O-sulfo groups. Figure 1 illustrates these two basic saccharides.  
 
 
Figure 1. Disaccharides involved in the natural synthesis of heparan sulfate.4 
 
Numerous enzymes and substrates are involved in the biosynthesis of such a complex 
compound. Heparin is a highly sulfated form of heparan sulfate that is used as an anticoagulant 
drug for the treatment of various thromboembolic and cardiovascular disorders. Compared to the 
widespread biologic activities of heparan sulfate, heparin specifically has high anticoagulation 
activity. The patient population that uses heparin is immense, which is why production has 
always remained a concern. Historically, heparin has been commonly extracted from porcine 
intestines as a naturally occurring substance. Although relatively inexpensive, this process has 
proven to be time-consuming, inefficient, and inconsistent. Particularly, a massive recall in 2007 
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was issued due to contaminated products that led to severe adverse effects and even death in 
many patients.1 
Currently, there are three forms of heparin that are approved by the FDA: unfractionated 
heparin (UFH), low-molecular weight heparin (LMWH), and fondaparinux (Arixtra). The 
production of UFH and LMWH depends on animal sources. On the other hand, Arixtra is fully 
synthetic but does not contain the full clinical benefits of UFH and LMWH. In Dr. Liu’s lab, the 
primary focus is to work towards the mass synthetic production of an ultra-low molecular weight 
heparin drug using methods that are both efficient in cost and resources. Although synthetic 
production is complicated, many risks of using animal sources pertaining to safety, 
contamination, and consistency can be eliminated. Additionally, synthetic heparin can be 
potentially engineered to contain other beneficial properties that do not exist in UFH and LMWH 
from natural sources.  
To date, the Liu lab has been successful in producing hundreds of milligrams of heparin 
using a large-scale process that involves recombinant biosynthetic enzymes and co-factor 
recycling. As shown in Figure 2, the chemoenzymatic synthesis of heparan sulfate involves 
numerous steps with varying enzymes and co-factors. 
 
Figure 2. Chemoenzymatic synthesis of heparan sulfate.4 
 
For this project, I focused on optimizing a (Kfia, UDP-GlcNTFA), b (pmHS2, UDP-
GlcUA), and c (Kfia, UDP-GlcNAc) as shown in Figure 2. Kfia and pmHS2 are two bacterial 
glycosyltransferases expressed in E. coli that are substitutes for the biosynthetic enzymes. These 
bacterial enzymes are involved in elongating the heparan sulfate backbone. UDP-GlcNTFA 
(uridine diphosphate N-trifluoroacetylglucosamine) and UDP-GlcUA (uridine diphosphate 
glucuronic acid) are the corresponding key substrates to these enzymes.4,5 Kfia and pmHS2 have 
the same functions and are interchangeable in reactions that require either enzyme. In the Liu 
lab, pmHS2 was used in place of Kfia to increase the efficiency of production. pmHS2 and the 
cofactors are synthesized and purified from E. coli crude bacterial lysates that are made with 
recombinant DNA technology, which significantly reduce production costs. 
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As seen in Figure 2, the disaccharide unit can be used to construct either ULMW heparin 
construct 1 (left) or ULMW heparin construct 2 (right). In comparison to the formation of 
construct 2, the steps to forming construct 1 are much more simplified. The a, b, and c in Figure 
2 are mainly involved in the synthesis of the pentamer, which is eventually transformed to 
construct 1. Therefore, my role in this project involves further improving the efficiency and 
efficacy of some of the steps involved in the synthesis of the simpler construct 1. This included 
optimization of the reagents as well as working on the processes of purification and production. 
Specifically, my project consisted of working on four different key components of the synthetic 
process and finding solutions for any problems I encountered. There were three main objectives 
for this project, as outlined below.  
 
1. Objective 1: To determine the pH stability of UDP-GlcNTFA. 
 
Figure 3. Charge attraction between UDP-GlcNTFA and an anion exchange 
column at a higher pH (greater than 7.5). 
 
Background: As described earlier, UDP-GlcNTFA is a key substrate involved in 
the chemoenzymatic synthesis of heparan sulfate. In the lab, UDP-GlcNTFA is 
isolated from a mixture of proteins in a bacterial lysate that is run through a 
Dowex anion exchange column that is positively charged. At a higher pH, the 
UDP component of UDP-GlcNTFA becomes negatively charged which would 
hypothetically allow it to bind better to the positively charged column for 
subsequent elution. This would ideally yield more purified UDP-GlcNTFA 
product that can be used by the lab for reactions that require UDP-GlcNTFA as a 
substrate. With UDP-GlcNTFA, the UDP component is stable at a higher pH but 
unfortunately the NTFA component is structurally more sensitive to higher pHs. 
Therefore, my role involved testing the stability of UDP-GlcNTFA at various 
pHs. 
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2. Objective 2: To determine the optimal conditions to perform the conversion of 
UDP-glucose to UDP-GlcUA by manipulating variables such as the amount of 
LADH crude lysate, concentration of UDP-glucose, and temperature of the 
reaction. 
 
Figure 4. Conversion of UDP-glucose to UDP-GlcUA2,3 
 
Background: As described earlier, UDP-GlcUA is a key substrate to enzymes 
involved in the chemoenzymatic synthesis of heparan sulfate. The synthesis of 
UDP-GlcUA involves multiple steps, with the final step being the conversion of 
UDP-glucose to UDP-GlcUA using the enzymes UDP-glucose dehydrogenase 
(UDGH) and lactate dehydrogenase (LADH). Ideally, a conversion of about 90-
100% of UDP-glucose to UDP-GlcUA is desired. Before I started this project, Dr. 
Pagadala was applying ethanol and heat precipitation to this reaction, which 
yielded 90% conversion. The problem with using ethanol and heat is that the 
majority of the reactant (UDP-glucose) is lost in the process. Therefore, the 
overall amount of product (UDP-GlcUA) yielded is less even though the 
conversion rate is good. With this in mind, Dr. Pagadala started performing 
conversion reactions without the use of ethanol and heat. In doing so, these 
reactions resulted in a suboptimal yield of UDP-GlcUA with <70% conversion. 
My role for this project was to manipulate different variables to determine if any 
of them would optimize the amount of UDP-GlcUA yielded from the reaction 
under the conditions of no ethanol or heat.  
 
3. Objective 3: To efficiently purify pmHS2 from crude bacterial lysate   
 
Background: As described earlier, pmHS2 is one of the essential enzymes 
involved in the chemoenzymatic synthesis of heparan sulfate. The lab cultures 
crude E. coli lysates, which are mixtures of many proteins including pmHS2. 
From that mixture, the objective was to isolate and purify pmHS2 to use for 
heparin synthesis. The purification process requires column chromatography with 
a column that is packed with nickel. The goal was to efficiently yield a large 
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amount of pmHS2 that is as pure as possible to use for reactions involved in 
heparin synthesis. 
 
The Liu lab has continued to work towards becoming more efficient by using the least 
amount possible of reactants, substrates, enzymes, and materials to yield more products. My role 
with this project was to optimize existing processes and purify various reagents involved in the 
production of synthetic heparin. By working towards efficient use of resources and processes 
with the end result of greater yields, the goal is the decrease the overall costs of manufacturing 
synthetic heparin for large-scale commercial use. 
 
Methods 
 
Objective 1. UDP-GlcNTFA pH Stability Test  
 
Tris buffer 50 mM (pH 7.5, 8.5, or 9.5) 5 uL 
UDP-GlcNTFA 90 uL 
Water 5 uL 
Total 100 uL 
 
In previous experiments performed in the lab, UDP-GlcNTFA was kept in a Tris buffer with a 
pH of 7.5, which is a neutral pH. Tris buffers with a pH of 8.5 or 9.5 were arbitrarily chosen to 
test the stability of UDP-GlcNTFA at higher pHs. Three batches of 100 uL were made with the 
only variable being the pH of the Tris buffer (7.5, 8.5, or 9.5). All batches were then incubated at 
room temperature (21 °C) and run through mass spectrometry to determine the extent of any 
degradation of UDP-GlcNTFA. 
 
Objective 2. Optimizing the conversion of UDP-glucose to UDP-GlcUA 
 
I. Amount of LADH crude lysate 
 
 Set 1 Set 2  Set 3 
UDP-glucose [10 mM]; final 
[5 mM] with Tris [1 M] and 
MgSO4 [1 M] 
5 mL 5 mL 5 mL  
Pyruvate [1 M] 0.75 mL 0.75 mL 0.75 mL 
NADH [0.1 M] 100 uL 100 uL 100 uL 
Pure UDGH [3 mg/mL] 400 uL 400 uL 400 uL 
Water 4 mL 4 mL 4 mL 
LADH  0.1 mL  0.2 mL (x) 0.4 mL 
Total 10.35 mL 10.45 mL 10.65 mL 
 
Three separate conversion reactions with a total of approximately 10 mL were made with the 
only variable being the volume of LADH. The variable x was arbitrarily set at 0.2 mL and 
variations were made with 0.5x (0.1 mL) and 1.5x (0.4 mL). After the three mixtures were made, 
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they were incubated overnight in a 30°C water bath. After incubation, 450 uL samples were 
drawn to analyze the UDP-GlcUA product using HPLC. 
 
II. Temperature of the reaction from glucose to UDP-glucose 
 
 UDP-glucose [5 mM] UDP-glucose [10 mM] 
0.5 M ATP 1.1 mL 2.2 mL 
0.5 M UTP 1 mL 2 mL 
1 M glucose 500 uL 1000 uL 
1 M MnCl2 400 uL 800 uL 
Enzymes Set 1 
(UGP1/Glk/PPA) +  
Enzymes Set 2 
(UGP1/Glk/PGM2) 
4 mL 8 mL 
100 mM glucose-1-phosphate 100 uL 200 uL 
Tris pH 7.5 [1 M] 2.5 mL 5 mL 
Water 90 mL 80 mL 
Total 100 mL 100 mL 
 
Two separate mixtures were made to convert glucose to UDP-glucose with final concentrations 
of either 5 mM or 10 mM. After each 100 mL mixture was made, 50 mL was incubated 
overnight in a 30°C water bath and the other 50 mL incubated in a 37°C water bath. After 
incubation, 10 uL of each mixture was drawn and mixed with 500 uL of water in an Eppendorf 
tube. After Eppendorf tubes were centrifuged for 2 minutes, 450 uL samples were drawn to 
analyze the UDP-glucose product using high performance liquid chromatography (HPLC) to 
separate the individual components of the sample.  
 
III. Concentration of UDP-glucose and temperature of the reaction from UDP-glucose to 
UDP-GlcUA  
 
 UDP-glucose [5 mM] UDP-glucose [10 mM] 
UDP-glucose [10 mM] 250 mL 500 mL 
Tris pH 7.5 [1 M] 12.5 mL 12.5 mL 
MgSO4 [5 mM] 1.25 mL 1.25 mL 
Pyruvate [1 M] 25 mL 25 mL 
NADH [0.15 M] 2 mL 2 mL 
LADH crude lysate 10 mL 10 mL 
UDGH pure 5 mL 5 mL  
Water 200 mL  0 mL 
Total 505.75 mL 555.75 mL  
*Note: Total volume of the conversion reaction was gradually scaled up from 60 mL to 120 mL to about 500 mL as 
shown in the table.  
 
Once UDP-glucose was made, it was then converted to UDP-GlcUA under the conditions of 
incubation in either a 30°C or 37°C water bath to determine whether either UDP-glucose 
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concentration or temperature were variables in the overall conversion to UDP-GlcUA. After 
incubation, 450 uL samples were drawn to analyze the UDP-GlcUA product using HPLC. In this 
case, the area under the curve (AUC) of the UDP-glucose peak compared to the AUC of the 
UDP-GlcUA peak indicated how much UDP-glucose was converted to UDP-GlcUA. 
 
 
Figure 5. Schematic of testing the variables of UDP-glucose concentration and reaction 
temperature 
 
Objective 3. Purification of pmHS2  
 
1. Make buffers needed for nickel column chromatography. 15 mL Sepharose Fast Flow 
nickel columns are used. 
a. Buffer A is used to promote pmHS2 protein binding to the nickel column. Each 
200 mL contains: 
i. 198 mL of Tris pH 7.5 [50 mM] and NaCl [500 mM]  
ii. 2 mL of imidazole [3 M] 
b. Buffer B contains imidazole, which assists in the collection of purified pmHS2. 
Each 100 mL of Buffer B contains: 
i. 90 mL of Tris pH 7.5 [50 mM] and NaCl [500 mM]  
ii. 10 mL of imidazole [3 M] 
2. Wash three connected nickel columns (column volume of 45 mL) with water. 
3. Equilibrate columns with 50 mL of buffer A.  
4. Centrifuge 6 L of E. coli culture and add 240 mL of buffer A to the cell pellet. Shake 
well. (Note: 1 L of culture was used initially and then eventually scaled up to 6 L) 
5. Keep the tubes on ice and sonicate to lyse the cells. Sonicate each tube for 30 seconds.  
6. After sonication, centrifuge (40,000 g) the tubes to spin down the debris and then 
separate the soluble protein supernatant from the top.  
7. The crude lysate contains the mixture of proteins (including pmHS2) from the lysed cells. 
Load the lysate through the nickel column. The pmHS2 protein contains a negatively 
charged histidine tag that will promote binding to the positively charged nickel column.  
8. Wash the column with buffer A (approximately 50 mL) to wash off any loosely bound, 
non-specific proteins that are bound to the column. 
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9. Using buffer B, elute pmHS2 from the column into 5 mL fractions. Buffer B contains 
imidazole, which allows collection of purified pmHS2 by disrupting the association 
between nickel and the histidine tag. 
10. The 5 mL fractions contain varying amounts of pmHS2, which are determined by UV 
absorbance at 280 nm. The fractions containing significant amounts of pmHS2 are 
pooled. 
 
 
Figure 6. Schematic of pmHS2 purification method using nickel column chromatography 
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Results 
 
Objective 1. UDP-GlcNTFA pH Stability Test  
 
 
Figure 7. Mass spectrum of UDP-GlcNTFA (pH 7.5) incubated at 21 °C overnight 
 
 
Figure 8. Mass spectrum of UDP-GlcNTFA (pH 8.5) incubated at 21 °C overnight 
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Figure 9. Mass spectrum of UDP-GlcNTFA (pH 9.5) incubated at 21 °C overnight 
 
 
Figure 10. Mass spectrum of UDP-GlcNTFA (pH 7.5) incubated at 4 °C overnight 
  
In the mass spectrums, the peaks at 329.8 and 660.2 represent the ionization charges on UDP-
GlcNTFA. The peak at 564.3 represents the amount of degraded UDP-GlcNTFA. Comparing 
Figures 7, 8, and 9, there was degradation of UDP-GlcNTFA regardless of the pH. However, the 
degradation peak at 564.3 increased with increasing pH. Thus, UDP-GlcNTFA was determined 
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to be most stable at a pH of 7.5. From there, UDP-GlcNTFA at a pH of 7.5 was incubated at 4 °C 
to determine whether temperature affected the extent of degradation. As shown in Figure 10, 
degradation was undetectable with a lower incubation temperature.  
 
Objective 2. Optimizing the conversion of UDP-glucose to UDP-GlcUA 
 
I. Temperature of the reaction from glucose to UDP-glucose 
 
 
Figure 11. HPLC chromatogram depicting the conversion of glucose to UDP-glucose 5 mM or 
10 mM after incubation in a 30°C water bath 
 
 
Figure 12. HPLC chromatogram depicting the conversion of glucose to UDP-glucose 5 mM or 
10 mM after incubation in a 37°C water bath 
UMP/AMP 
UDP-glucose 
UMP/AMP 
UDP-glucose 
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In Figures 11 and 12, the peak at ~8.5 min represents glucose and the peak at 10.0 min represents 
UDP-glucose. Based on the AUC of the peaks, approximately 60-80% of glucose was converted 
to UDP-glucose under the conditions of either a 30°C or a 37°C water bath. This conversion rate 
is consistent with what has been yielded previously in the lab.  
 
II. The conversion of UDP-glucose to UDP-GlcUA with the manipulation of the UDP-
glucose concentration, temperature of the reaction, and amount of LADH crude lysate 
 
 
Figure 13. HPLC chromatogram depicting the conversion of UDP-glucose to UDP-
GlcUA under the optimized conditions of UDP-glucose [5 mM], incubation in a 30°C 
water bath, and 0.1 mL of LADH crude lysate 
 
Many experiments were performed while manipulating the variables of UDP-glucose 
concentration, temperature of the reaction, and amount of LADH crude lysate. The best results 
were achieved with UDP-glucose concentration of 5 mM, incubation in a 30°C water bath, and 
using 0.1 mL of LADH. This is represented by Figure 13, which shows approximately 90% 
conversion rate from UDP-glucose (peak at 10 min) to UDP-GlcUA (peak at 15 min) based on 
the AUC.  
 
 
 
 
 
 
 
 
 
 
 
UDP-glucose 
UDP-GlcUA 
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Objective 3. Purification of pmHS2  
 
 
Figure 14. The amount of pmHS2 purified from each 6 L batch of E. coli culture is enough to 
convert 1 g of heparin monomer to 2-3 g of heparin 6mer 
 
 
Figure 15. The amount of pmHS2 required for each polymerization step from 1 g of heparin 
monomer to 2-3 g of heparin 6mer  
 
As depicted in Figures 14 and 15, the conversion of 1 g of monomer to 2-3 g of 6mer requires a 
total of 200 mg of pmHS2, which was purified from each 6 L batch of E. coli culture. 
 
 
Figure 16. Gel electrophoresis picture of the purified pmHS2 
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SDS-PAGE (PolyAcrylamide) gel electrophoresis is a method that is used to separate and 
analyze macromolecules (e.g. proteins) and their fragments based on size and charge. In Figure 
16, the thickest band represents pmHS2 in the eluent. Based on the thickness of the band, the 
purified pmHS2 eluent is more than 90% pure.  
 
Discussion 
 
Objective 1. UDP-GlcNTFA pH Stability Test  
 
From the results of the pH stability test, the mass spectrums show the stability of UDP-GlcNTFA 
at varying pHs and temperatures. The purpose of this experiment was to determine if UDP-
GlcNTFA could maintain its stability at higher pHs where it is more negatively charged, which 
would allow it to bind better to the positively charged anion exchange column. However, the 
results demonstrate that by trying to achieve a more negatively charged compound, this is 
compromised by having more compound degradation. Room temperature was also a significant 
factor that negatively affected the stability of UDP-GlcNTFA at higher temperatures regardless 
of pH. In conclusion, purification of UDP-GlcNTFA should be performed at a neutral pH of 7.5 
and maintained in the cold room at a temperature of 4°C. 
 
Objective 2. Optimizing the conversion of UDP-glucose to UDP-GlcUA 
 
Before the start of this project, the lab attempted to perform conversion reactions of UDP-
glucose to UDP-GlcUA without the use of ethanol or heat precipitation. However, this resulted 
in suboptimal yields (<70%) of UDP-GlcUA product. In the lab, a conversion of at least 90% of 
UDP-glucose to UDP-GlcUA is ideal. At first, we hypothesized that the amount of LADH crude 
lysate was contributing to the low conversion yield due to impurities in the lysate. Although 
LADH can hypothetically be purified from the crude mixture, the process of purifying every 
single enzyme involved in the synthesis of heparin is time-consuming and expensive. Therefore, 
the lab focuses on manipulating conditions of the reaction while using as few resources as 
possible. After performing multiple conversion reactions by adjusting the amount of LADH, it 
was found that using less LADH led to better conversion yields of UDP-glucose to UDP-GlcUA. 
However, the yield was still less than our goal of >90%. After manipulating other variables, we 
determined that using a lower concentration of UDP-glucose (5 mM versus 10 mM) yielded 
approximately 90% conversion. The theory is that if there is too much reactant (UDP-glucose) to 
begin with, some of the byproducts of the reaction will lead to substrate or product inhibition so 
that there is less conversion of reactant to product. In fact, it was found in later experiments after 
this project that using even less concentrated UDP-glucose at 2.5 mM yielded an even better 
conversion yield of >90%. As for manipulating the temperature of the conversion reactions 
(30°C versus 37 °C), we hypothesized that increasing the temperature would increase the 
reaction rate and increase the amount of product yielded. For the conversion reaction of glucose 
to UDP-glucose, incubation temperature did not impact the product yield. However, incubation 
temperature did make a difference in the subsequent conversion reaction of UDP-glucose to 
UDP-GlcUA. When this reaction was incubated at 37°C, there were more degraded enzymes and 
less conversion yield. After performing numerous reactions under different conditions, it was 
determined that the optimal conditions for the conversion of UDP-glucose to UDP-GlcUA were 
using the least amount of crude LADH, the lowest concentration of UDP-glucose, and an 
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incubation temperature of 30°C. When these conditions were met, more than 90% conversion 
yield to UDP-GlcUA was consistently achieved. 
 
 Conversion Yield (%) 
Before Project 
Reactions with ethanol and heat precipitation ~90%, variable 
Reactions without ethanol and heat 
precipitation 
<70% 
After Project (no ethanol or heat precipitation) 
Most amount of LADH crude <80% 
Least amount of LADH crude ~80% 
Least amount of LADH crude, UDP-glucose 
10 mM, 30°C or 37°C 
<80% 
Least amount of LADH crude, UDP-glucose 
2.5 or 5 mM, 37°C 
~80% 
Least amount of LADH crude, UDP-glucose 
2.5 or 5 mM, 30°C 
>90%, consistent 
Figure 14. Results of conversion yield percentages of reactions under different conditions 
 
Objective 3. Purification of pmHS2  
 
pmHS2 is an essential enzyme that is required for each elongation step to form the heparin 
polymer. 40 mL (200 mg) of pmHS2 was purified from E. coli crude lysate, which is enough to 
elongate 1 g of heparin monomer to yield 2-3 g of heparin hexamer. The pmHS2 was more than 
90% pure based on gel electrophoresis analysis.  
 
Conclusion 
 
The clinical significance of synthetic heparin created in the Liu lab is immense. Although 
synthesis is complicated, many risks of using animal sources pertaining to safety, contamination, 
and consistency can be eliminated. When striving to create a synthetic and pure product, one 
may simply use larger columns for elution, buy more expensive equipment, purify every single 
enzyme, or even resort to purchasing substrates that are needed in the synthetic process. 
However, these methods are not efficient in cost, resources, or time. In the lab, the goal is to use 
or create materials and resources in ways that are efficient so that the final product is 
reproducible and affordable. For this to happen, the lab pursues creative ways to modify different 
variables and reaction conditions. As you can see in the following table, the lab is able to 
produce the substrates UDP-glucose and UDP-GlcUA at a significantly lower cost than 
purchasing them.   
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Product Amount Commercial Cost Lab Cost 
UDP-GlcUA 1 gram $1420 $40 
UDP-glucose 1 gram $326 $20 
 
Overall, the idea is to tweak the reagents or the conditions of the reactions involved in the 
chemoenzymatic synthesis of heparin without having to purify every enzyme or reagent. Instead 
of attempting to purify enzymes and substrates involved in every single step, the lab focuses on 
purifying the end product which is much more efficient. Through my project, we were able to 
optimize the lab’s existing processes in order to enhance the efficiency of production. To date, 
the Liu lab has successfully produced grams of synthetic ULMWH by continuously working 
towards using the least amount of reagents and materials to achieve greater product yields. The 
Liu lab is currently working towards FDA approval of this pure, synthetic form of heparin with 
the ultimate goal of reducing manufacturing costs so that it can be mass-produced in clinical 
settings and be financially affordable for patients.  
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